$2.55T
Total marketcap
$182.75B
Total volume
BTC 50.08%     ETH 15.86%
Dominance

Vir Biotechnology VIR Stock

10.68 USD {{ price }} -0.743494% {{change_pct}}%
Exchange
NasdaqGS
Market Cap
1.44B USD
LOW - HIGH [24H]
10.59 - 10.8 USD
VOLUME [24H]
875.82K USD
{{ volume }}
P/E Ratio
0
Earnings per share
-4.59 USD

Vir Biotechnology Price Chart

Vir Biotechnology VIR Financial and Trading Overview

Vir Biotechnology stock price 10.68 USD
Previous Close 26.02 USD
Open 25.89 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 25.59 - 26.04 USD
52 Week Range 18.05 - 31.78 USD
Volume 642.05K USD
Avg. Volume 857.6K USD
Market Cap 3.48B USD
Beta (5Y Monthly) 0.255044
PE Ratio (TTM) N/A
EPS (TTM) -4.59 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 49.71 USD

VIR Valuation Measures

Enterprise Value 1.36B USD
Trailing P/E N/A
Forward P/E -5.2912426
PEG Ratio (5 yr expected) -0.89
Price/Sales (ttm) 7.7991514
Price/Book (mrq) 1.7655454
Enterprise Value/Revenue 3.058
Enterprise Value/EBITDA -4.944

Trading Information

Vir Biotechnology Stock Price History

Beta (5Y Monthly) 0.255044
52-Week Change 5.91%
S&P500 52-Week Change 20.43%
52 Week High 31.78 USD
52 Week Low 18.05 USD
50-Day Moving Average 25.26 USD
200-Day Moving Average 24.59 USD

VIR Share Statistics

Avg. Volume (3 month) 857.6K USD
Avg. Daily Volume (10-Days) 736.72K USD
Shares Outstanding 133.98M
Float 86.5M
Short Ratio 6.51
% Held by Insiders 14.24%
% Held by Institutions 73.82%
Shares Short 5.58M
Short % of Float 7.04%
Short % of Shares Outstanding 4.16%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin -32.19%
Operating Margin (ttm) -64.29%
Gross Margin -26.13%
EBITDA Margin -61.85%

Management Effectiveness

Return on Assets (ttm) -6.45%
Return on Equity (ttm) -7.23%

Income Statement

Revenue (ttm) 446.3M USD
Revenue Per Share (ttm) 3.36 USD
Quarterly Revenue Growth (yoy) -94.89%
Gross Profit (ttm) 1.03B USD
EBITDA -276062016 USD
Net Income Avi to Common (ttm) -143684000 USD
Diluted EPS (ttm) -1.06
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 2.25B USD
Total Cash Per Share (mrq) 16.8 USD
Total Debt (mrq) 128.73M USD
Total Debt/Equity (mrq) 6.53 USD
Current Ratio (mrq) 4.86
Book Value Per Share (mrq) 14.715

Cash Flow Statement

Operating Cash Flow (ttm) 987.38M USD
Levered Free Cash Flow (ttm) 853.38M USD

Profile of Vir Biotechnology

Country United States
State CA
City San Francisco
Address 499 Illinois Street
ZIP 94158
Phone 415 906 4324
Website https://www.vir.bio
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 576

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Q&A For Vir Biotechnology Stock

What is a current VIR stock price?

Vir Biotechnology VIR stock price today per share is 10.68 USD.

How to purchase Vir Biotechnology stock?

You can buy VIR shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Vir Biotechnology?

The stock symbol or ticker of Vir Biotechnology is VIR.

Which industry does the Vir Biotechnology company belong to?

The Vir Biotechnology industry is Biotechnology.

How many shares does Vir Biotechnology have in circulation?

The max supply of Vir Biotechnology shares is 135.03M.

What is Vir Biotechnology Price to Earnings Ratio (PE Ratio)?

Vir Biotechnology PE Ratio is now.

What was Vir Biotechnology earnings per share over the trailing 12 months (TTM)?

Vir Biotechnology EPS is -4.59 USD over the trailing 12 months.

Which sector does the Vir Biotechnology company belong to?

The Vir Biotechnology sector is Healthcare.

Vir Biotechnology VIR included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16103.45 USD
+0.82
4.52B USD 16094.17 USD 16247.59 USD 4.52B USD
NASDAQ Global Select Market Com NQGS 7837.41 USD
+0.85
7832.7 USD 7908.95 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq US Smart Pharmaceuticals NQSSPH 1454.2 USD
-0.47
1453.71 USD 1464.83 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2568.29 USD
+0.16
2566.7 USD 2581.47 USD
NASDAQ Biotechnology NBI 4337.34 USD
-0.65
4335.84 USD 4376.86 USD
NASDAQ HealthCare IXHC 986.88 USD
-0.25
986.44 USD 994.67 USD